Juvena Therapeutics Secures $41 Million To Accelerate The Discovery And Development Of Biologics For Chronic And Age-Related Diseases
Juvena Therapeutics Secures $41 Million To Accelerate The Discovery And Development Of Biologics For Chronic And Age-Related Diseases
11/08/22, 12:08 PM
Location
palo altoMoney raised
$41 million
Industry
therapeutics
biotechnology
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics pipeline targeting chronic and age-related diseases.
Company Info
Location
palo alto, california, united states
Additional Info
Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has been under-leveraged due to the complexity of identifying and screening such proteins. The company is developing a patent-pending computational drug discovery and development platform that is delivering novel biologics to address major unmet medical needs in chronic and age-related diseases by mining regenerative proteins secreted by stem cells. Juvena has generated hits and new drug targets across several therapeutic areas. To learn more about Juvena Therapeutics, visit JuvenaTherapeutics.com or follow the company on LinkedIn @Juvena-Therapeutics.